Fully closed-loop insulin therapy safe, effective in diabetes patients requiring dialysis: Study

Written By :  MD Editorial Team
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-10-23 04:30 GMT   |   Update On 2021-10-23 06:52 GMT

UK: A new study in the journal Nature Medicine has reported that fully closed-loop insulin therapy improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis. Management of diabetes in this population is challenging for both patients and healthcare professionals as it poses severe complications of...

Login or Register to read the full article

UK: A new study in the journal Nature Medicine has reported that fully closed-loop insulin therapy improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis. 

Management of diabetes in this population is challenging for both patients and healthcare professionals as it poses severe complications of the kidney and heart. Closed-loop systems are increasingly being applied for the management of type 1 diabetes. However, the use of this technology in people with type 2 diabetes is limited to the inpatient setting including those on hemodialysis.

Charlotte K. Boughton, Cambridge University Hospitals NHS Foundation Trust, Wolfson Diabetes and Endocrine Clinic, Cambridge, UK, and colleagues, therefore, aimed to evaluate the safety and efficacy of fully closed-loop insulin therapy compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis.

The study was an open-label, multinational, two-center, randomized crossover trial, 26 adults with type 2 diabetes requiring dialysis (17 men, 9 women, average age 68 ± 11 years (mean ± s.d.), diabetes duration of 20 ± 10 years) underwent two 20-day periods of unrestricted living, comparing the Cambridge fully closed-loop system using faster insulin aspart ('closed-loop) with standard insulin therapy and a masked continuous glucose monitor ('control') in random order. The primary endpoint was a time in target glucose range (5.6–10.0 mmol l−1).

 A total of 13 participants received closed-loop first and thirteen received control therapy first.

The results of the study were

• The proportion of time in target glucose range (5.6–10.0 mmol l−1; primary endpoint) was 52.8 ± 12.5% with closed-loop versus 37.7 ± 20.5% with control; mean difference, 15.1 percentage points.

• Mean glucose was lower with closed-loop than control (10.1 ± 1.3 versus 11.6 ± 2.8 mmol l−1). Time in hypoglycemia (<3.9 mmol l−1) was reduced with closed-loop versus control (median (IQR) 0.1 versus 0.2).

Boughton and team concluded that "Fully closed-loop improved glucose control and reduced hypoglycemia compared with standard insulin therapy in adult outpatients with type 2 diabetes requiring dialysis." They also stated that no severe hypoglycemia events occurred during the control period, whereas one severe hypoglycemic event occurred during the closed-loop period, but not during closed-loop operation.

For further information: https://doi.org/10.1038/s41591-021-01453-z

Tags:    
Article Source : Nature Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News